Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Trends in psychotropic use among older adults with dementia in Korean long-term care hospitals across the COVID-19 pandemic: a national longitudinal study.

Frontiers in public health·2026
Same author

Erratum to "'Site-specific enrichment of highly sialylated N-glycans in an erythropoietin-hybrid Fc fusion protein" [Eur. J. Pharm. Biopharm. 226 (2026) 115147].

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Limited Cross-Neutralization of Emerging SARS-CoV-2 BA.3.2.2 After LP.8.1-Updated Vaccination.

Journal of medical virology·2026
Same author

Differential Wound Healing Potential of Tonsil Parenchymal and Epithelial Mesenchymal Stromal Cell-Derived Exosomes.

Tissue engineering and regenerative medicine·2026
Same author

Site-specific enrichment of highly sialylated N-glycans in an erythropoietin-hybrid Fc fusion protein.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026
Same author

Clinical outcomes associated with Korean medicine home-visit care for patients with cognitive impairment: a multi-center retrospective observational study.

Scientific reports·2026

関連する実験動画

Updated: Sep 9, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.1K

N-デグロンベースのPROTACターゲティングPLK1: 子宮頸がんに対する潜在的な治療戦略

Pethaiah Gunasekaran1,2, Sang Chul Shin3, Yeon Sil Hwang2

  • 1Division of Magnetic Resonance, Korea Basic Science Institute (KBSI), Ochang, Cheongju 28119, Republic of Korea.

Pharmaceutics
|August 28, 2025
PubMed
まとめ

新しいPROTAC分子であるNC1は,子宮頸がん細胞におけるPolo型キナーゼ1 (PLK1) を効果的に分解し,臨床前モデルでは化学抵抗を克服し,腫瘍の成長を抑制する見込みを示している.

キーワード:
N-デグロンN端のルールの経路PLK1 についてプロタック抗がん剤

さらに関連する動画

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

関連する実験動画

Last Updated: Sep 9, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.1K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

科学分野:

  • 腫瘍学
  • 分子生物学
  • 薬物の発見

背景:

  • 子宮頸がんは 世界的な健康問題です
  • 現在の化学療法の選択肢は抵抗性によって制限されており,新しい治療戦略が必要である.
  • ポロ型キナーゼ1 (PLK1) は子宮頸がんにおいて過剰発現し,潜在的な治療標的である.

研究 の 目的:

  • PLK1を標的とする新しいタンパク質分解標的キメラ (PROTAC) の開発.
  • このPROTACがPLK1を分解し,子宮頸がん細胞に与える影響を調査する.
  • 臨床前モデルでのPROTACの治療の可能性を評価する.

主な方法:

  • Nエンドル経路を介してPLK1タンパク質を標的とする新しいPROTAC,NC1の開発.
  • HeLa細胞におけるPLK1タンパク質減少の評価
  • PBD-NC1複合体の構造分析とイソテルミック・タイトレーション・カロメトリー (ITC) による結合親和度決定.
  • 細胞活性のインビトロ評価,細胞サイクル停止,アポトーシスの誘導.
  • HeLa 異種移植マウスモデルにおける腫瘍増殖抑制の in vivo 評価

主要な成果:

  • PROTAC NC1はHeLa細胞におけるPLK1タンパク質の分解を成功裏に誘導した.
  • 構造研究により,NC1とPLK1PBDとの主要結合相互作用が確認され,ITCによって決定された結合親和度は6. 06μMであった.
  • NC1は,細胞活性の低下 (IC50 5. 23μM),G2/ M相停止,アポトーシスの誘導を含む,重要な抗癌効果をインビトロで示した.
  • ネズミのモデルでは,NC1が腫瘍の成長を抑制することが示された.

結論:

  • PLK1を標的とするN-デグロンベースのPROTACは,がん治療において有望な戦略である.
  • 開発されたPROTAC,NC1は,子宮頸がんにおける化学抵抗を克服する有意な可能性を示しています.
  • この研究は,将来の子宮頸がん治療戦略のための新しいPLK1標的型PROTACの開発をサポートします.